Boston Scientific (BSX) Net Cash Flow (2009 - 2026)

Boston Scientific (BSX) has 18 years of Net Cash Flow data on file, last reported at -$503.0 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 283.58% year-over-year to -$503.0 million; the trailing twelve-month figure through Mar 2026 stood at $722.0 million (up 144.79% YoY), and the FY2025 full-year result was $1.5 billion, up 442.24% from the prior year.
• Net Cash Flow declined to -$503.0 million in Q1 2026, from $668.0 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $1.4 billion in Q1 2024 to a low of -$2.0 billion in Q4 2024.
• A 5-year average of -$31.8 million and a median of -$66.0 million in 2022 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow soared 6844.44% in 2022 and plunged 2411.11% in 2024, its largest moves.
• Tracing BSX's Net Cash Flow over 5 years: stood at $625.0 million in 2022, then sank by 112.96% to -$81.0 million in 2023, then sank by 2411.11% to -$2.0 billion in 2024, then jumped by 132.84% to $668.0 million in 2025, then tumbled by 175.3% to -$503.0 million in 2026.
• Business Quant data shows BSX's Net Cash Flow at -$503.0 million in Q1 2026, $668.0 million in Q4 2025, and $737.0 million in Q3 2025.